Cite
HARVARD Citation
Bazarbachi, A. et al. (2019). Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party1. Cancer. 125 (1), pp. 90-98. [Online].